Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
26.50    0.00 (0.00%)
Bid:
26.00
Ask:
27.00
Spread: 1.00 (3.846%)
Market Cap: £133.43m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading and Operational Update

31 Mar 2026 07:00

RNS Number : 7112Y
Duke Capital Limited
31 March 2026
 

31 March 2026

Duke Capital Limited

 

("Duke Capital", "Duke" or the "Company")

 

Trading and Operational Update

 

Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to provide guidance on its trading for the fourth quarter of the financial year ending 31 March 2026 ("Q4 FY26").

 

Trading Update

 

Duke expects to achieve record recurring cash revenue* of £7.0 million in Q4 FY26. This represents an 8% year-on-year increase on Q4 FY25 (£6.5 million) and an increase of £0.2 million over the prior quarter, which saw the Company deliver recurring cash revenue of £6.8 million.

 

Total cash revenue for Q4 FY26 is expected to total £8.5 million following receipt of the final tranche of deferred consideration from the Fabrikat exit in February 2024.

 

Overview of quarterly revenue growth:

 

 

Recurring Cash Revenue*

Total Cash Revenue**

Q4 FY25

£6.5 million

£6.5 million

Q1 FY26

£6.6 million

£6.6 million

Q2 FY26

£6.6 million

£6.6 million

Q3 FY26

£6.8 million

£6.8 million

Q4 FY26 forecast

£7.0 million

£8.5 million

 

* Recurring cash revenue excludes exit premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's partners plus exit premium receipts and cash gains from equity sales

 

Fabrikat exit

 

· Duke invested £6.2 million into Fabrikat in February 2021 and received £3.2 million in distributions until the sale of the company in March 2024 to Metalogalva - Irmãos Silvas, SA, a Portuguese company in the area of engineering and steel protection.

· Upon sale, Duke received total proceeds of £11.4 million, including £1.5 million in deferred payments, which resulted in a 35% IRR over a five-year period.

 

Neil Johnson, CEO of Duke Capital, said:

 

"We are delighted to report another record quarter of recurring cash revenue for Q4 FY26, rounding off a strong finish to the financial year. This performance reflects the resilience of our business model in navigating a challenging macroeconomic environment. Whilst the Bank of England's decision to hold rates in March reflects the ongoing uncertainty in global markets, including the situation in the Middle East, our business model has demonstrated its ability to perform across market cycles.

 

"The receipt of the final deferred consideration from the Fabrikat exit demonstrates our ability to provide upside for shareholders upon exits. While exits are expected in our business model, the timing of them is dependent on the broader fundraising environment. We are pleased to show both the resilience of our recurring revenue and upside from exits in the current quarter, and we look forward to updating shareholders further in our annual results."

 

 

***ENDS***

 

For further information, please visit https://dukecapital.com/ or contact:

 

Duke Capital Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 231 816

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson 

+44 (0) 207 220 0500

 

Canaccord Genuity Limited

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (Financial Communications)

Robin Tozer / Alice Cho / Gwen Samuel

+ +44 (0) 20 3757 6882 dukecapital@secnewgate.co.uk

 

 

About Duke Capital

 

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt.

 

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business.

 

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. Its three investment pillars are capital preservation, attractive dividend yield, and to provide upside upon exits.

 

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKKBQFBKDCNN
Date   Source Headline
2nd Jul 20207:00 amRNSScrip Dividend Reference Price
18th Jun 20207:00 amRNSFollow-on contribution to royalty partner
17th Jun 20207:01 amRNSDividend Declaration
17th Jun 20207:00 amRNSIssue of Equity
14th May 20202:05 pmRNSSecond Price Monitoring Extn
14th May 20202:00 pmRNSPrice Monitoring Extension
14th May 20207:00 amRNSTrading and Dividend Update
6th May 20204:42 pmRNSSecond Price Monitoring Extn
6th May 20204:36 pmRNSPrice Monitoring Extension
5th May 20204:45 pmRNSHolding(s) in Company
2nd Apr 20207:00 amRNSTrading Update re: COVID-19
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:35 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSFollow-on contribution to royalty partner
11th Mar 20207:01 amRNSDividend Declaration & Trading Update
11th Mar 20207:00 amRNSDirectorate Change
30th Jan 20207:00 amRNSFollow-on contribution to royalty partner
23rd Jan 202012:35 pmRNSHolding(s) in Company
13th Jan 20207:00 amRNSPortfolio Update
9th Jan 20205:23 pmRNSHolding(s) in Company
9th Jan 20205:20 pmRNSHolding(s) in Company
16th Dec 20197:00 amRNSDividend Declaration
6th Dec 20197:01 amRNSLong Term Incentive Plan Awards
6th Dec 20197:00 amRNSInterim Results
4th Nov 20197:00 amRNSPaydown of Revolving Credit Facility
1st Nov 20197:00 amRNSFollow-on contribution to royalty partner
31st Oct 20193:19 pmRNSDirectors' Dealings
30th Oct 20191:55 pmRNSResult of EGM and Issue of £17.5 million of Equity
25th Oct 20197:00 amRNSNotification of major holdings
16th Oct 201911:26 amRNSResult of Annual General Meeting
7th Oct 20197:00 amRNSResult of Retail Offer and Open Offer Details
4th Oct 20194:31 pmRNSRetail Offer via PrimaryBid.com
4th Oct 20194:30 pmRNSFundraising of up to £20 million
19th Sep 20197:00 amRNSIncreased Interim Dividend & Dividend Declaration
18th Sep 20197:00 amRNSPosting of Report & Accounts and Notice of AGM
10th Sep 20197:00 amRNSIncreased £30M Credit Facility on Improved Terms
9th Sep 20197:00 amRNSFiscal 2019 Final Results
29th Aug 20197:00 amRNSFollow-On Contribution and Restructuring
14th Aug 20197:00 amRNSUpdate and Notice of Results
25th Jul 20195:51 pmRNSNotification of major holdings
19th Jun 20197:00 amRNSDividend Declaration
28th May 20197:00 amRNSFollow-on contribution to royalty partner
14th May 20191:00 pmRNSModification of Partners' Agreements - Amendment
14th May 20197:00 amRNSModification of Partners' Agreements
7th May 20197:00 amRNSNotification of major holdings
22nd Mar 20197:00 amRNSDirector's Dealings
19th Mar 20197:00 amRNSDividend Declaration
14th Mar 20197:00 amRNSChange of Adviser
19th Feb 20197:00 amRNSNew Royalty Finance Agreement
5th Feb 20191:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.